or Try an Advanced Search...

    Technical Analysis for ACAD - ACADIA Pharmaceuticals Inc.

    Grade Last Price % Change Price Change
    F 16.70 -1.71% -0.29
    ACAD closed up 1.01 percent on Monday, April 22, 2024, on 61 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    Earnings due: May 6
    *** please verify all earnings dates ***
    4 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical ACAD trend table...
    Date Alert Name Type % Chg
    Stochastic Reached Oversold Weakness -1.71%
    Gapped Up Strength -1.71%
    Oversold Stochastic Weakness -1.71%
    New 52 Week Closing Low Bearish -0.71%
    Lower Bollinger Band Touch Weakness -0.71%
    180 Bearish Setup Bearish Swing Setup -2.17%
    Narrow Range Bar Range Contraction -2.85%
    Lower Bollinger Band Walk Weakness -2.85%
    Gapped Up Strength -2.85%
    Oversold Stochastic Weakness -2.85%
    Older End-of-Day Signals for ACAD ...

       Recent Intraday Alerts

    Alert Time
    Down 2 % about 3 hours ago
    Down 1% about 4 hours ago
    60 Minute Opening Range Breakdown about 5 hours ago
    Fell Below Previous Day's Low about 5 hours ago
    10 DMA Resistance about 5 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    ACAD Chart by TradingView
    Basic chart:

    Profile

    ACADIA Pharmaceuticals Inc. Description

    ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. The company has a pipeline of product candidates led by pimavanserin, which is in Phase III development stage for the treatment of Parkinson's disease psychosis. It is also developing pimavanserin that has completed Phase II co-therapy trials for the treatment of schizophrenia; and is in Phase II clinical trials for the treatment of Alzheimer's disease psychosis. In addition, the company, through collaboration with Allergan, Inc., is developing alpha adrenergic agonists, which are in Phase II clinical trials for the treatment of chronic pain; and muscarinic agonist that is in Phase I clinical trials for the treatment of glaucoma. Further, it is developing two advanced preclinical programs directed at Parkinson's disease and other neurological disorders. The company was formerly known as Receptor Technologies, Inc. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Medication Alzheimer's Disease Chemical Compounds Parkinson's Disease Chronic Pain Schizophrenia Neurological Disorders Central Nervous System Disorders Nervous System Disorders Glaucoma Treatment Of Parkinson's Disease Urological Disorders Treatment Of Glaucoma Treatment Of Chronic Pain Treatment Of Alzheimer's Disease Treatment Of Schizophrenia Psychosis

    Is ACAD a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 22 Acadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada
    Apr 17 Acadia Pharmaceuticals Presents New DAYBUE™ (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual Meeting
    Apr 11 3 Pharma Stocks to Sell in April Before They Crash & Burn
    Apr 10 ACADIA Pharmaceuticals Inc CEO Stephen Davis Sells 26,574 Shares
    Apr 2 Acadia Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development
    Apr 1 Acadia Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
    Mar 28 ACADIA Pharmaceuticals Inc CEO Stephen Davis Sells 17,714 Shares
    Mar 14 3 Pharma Stocks to Sell in March Before They Crash & Burn
    Mar 13 Acadia Pharmaceuticals to Participate in the UBS Virtual CNS Day
    Mar 13 Evaluating Acadia's Market Position Following Pimavanserin's Clinical Setback
    See more ACAD news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 33.9069
    52 Week Low 16.6
    Average Volume 1,897,529
    200-Day Moving Average 24.68
    50-Day Moving Average 20.83
    20-Day Moving Average 17.67
    10-Day Moving Average 17.25
    Average True Range 0.64
    RSI (14) 31.03
    ADX 49.18
    +DI 9.26
    -DI 29.96
    Chandelier Exit (Long, 3 ATRs) 17.07
    Chandelier Exit (Short, 3 ATRs) 18.52
    Upper Bollinger Bands 18.74
    Lower Bollinger Band 16.61
    Percent B (%b) 0.18
    BandWidth 12.08
    MACD Line -1.03
    MACD Signal Line -1.18
    MACD Histogram 0.1455
    Fundamentals Value
    Market Cap 2.79 Billion
    Num Shares 164 Million
    EPS -0.91
    Price-to-Earnings (P/E) Ratio -18.67
    Price-to-Sales 6.85
    Price-to-Book 11.94
    PEG Ratio -0.42
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 17.59
    Resistance 3 (R3) 17.64 17.49 17.49
    Resistance 2 (R2) 17.49 17.34 17.47 17.46
    Resistance 1 (R1) 17.24 17.24 17.17 17.19 17.42
    Pivot Point 17.09 17.09 17.05 17.07 17.09
    Support 1 (S1) 16.84 16.94 16.77 16.79 16.56
    Support 2 (S2) 16.69 16.84 16.67 16.52
    Support 3 (S3) 16.44 16.69 16.49
    Support 4 (S4) 16.39